These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17631592)

  • 1. Response evaluation: beyond RECIST.
    Eisenhauer EA
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix29-32. PubMed ID: 17631592
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?
    Pignatti F; Hemmings R; Jonsson B
    Eur J Cancer; 2011 Aug; 47(12):1759-62. PubMed ID: 21641204
    [No Abstract]   [Full Text] [Related]  

  • 3. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized phase II trials: misleading and unreliable.
    Stewart DJ
    J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract]   [Full Text] [Related]  

  • 5. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 6. Progression-free survival: helpful biomarker or clinically meaningless end point?
    Venook AP; Tabernero J
    J Clin Oncol; 2015 Jan; 33(1):4-6. PubMed ID: 25366687
    [No Abstract]   [Full Text] [Related]  

  • 7. General and statistical hierarchy of appropriate biologic endpoints.
    Sargent D
    Oncology (Williston Park); 2006 May; 20(6 Suppl 5):5-9. PubMed ID: 16773839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Randomizations!].
    Piedbois P; Buyse M
    Cancer Radiother; 1998 Dec; 2(6):663-4. PubMed ID: 9922769
    [No Abstract]   [Full Text] [Related]  

  • 9. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactive oxygen species may have antitumor activity in metastatic melanoma.
    Tuma RS
    J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
    [No Abstract]   [Full Text] [Related]  

  • 12. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
    Vickers AJ; Ballen V; Scher HI
    Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 14. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 15. [ASCO 2006 Annual Meeting, Atlanta, June 2-6, 2006. Focus on gastrointestinal tumors].
    Bonetti A; Cascinu S; Falcone A; Zaniboni A
    Tumori; 2006; 92(4):suppl 10-43. PubMed ID: 17036537
    [No Abstract]   [Full Text] [Related]  

  • 16. Predicting success in phase III studies from phase II results: a new paradigm is needed.
    Leff R; Andrews M
    J Clin Oncol; 2008 Jul; 26(21):3653-4; author reply 3654-5. PubMed ID: 18640948
    [No Abstract]   [Full Text] [Related]  

  • 17. Why do phase III clinical trials in oncology fail so often?
    Amiri-Kordestani L; Fojo T
    J Natl Cancer Inst; 2012 Apr; 104(8):568-9. PubMed ID: 22491346
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of tumor burden versus progression-free survival for Phase II decision making.
    Fridlyand J; Kaiser LD; Fyfe G
    Contemp Clin Trials; 2011 May; 32(3):446-52. PubMed ID: 21266203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model aims to reduce discrepancy between phase II, phase III trials.
    Reynolds T
    J Natl Cancer Inst; 2000 Oct; 92(19):1554-5, 1556. PubMed ID: 11018083
    [No Abstract]   [Full Text] [Related]  

  • 20. Patupilone in cancer treatment.
    Bystricky B; Chau I
    Expert Opin Investig Drugs; 2011 Jan; 20(1):107-17. PubMed ID: 21142807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.